Healthcare [ 5/13 ] | Biotechnology [ 44/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 2, 23 | -0.26 Increased by +44.68% | -0.25 Decreased by -4% |
| Aug 3, 23 | -0.26 Increased by +43.48% | -0.22 Decreased by -18.18% |
| May 4, 23 | -0.23 Increased by +43.9% | -0.27 Increased by +14.81% |
| Mar 7, 23 | -0.23 Increased by +54.9% | -0.27 Increased by +14.81% |
| Nov 3, 22 | -0.47 Increased by 0% | -0.46 Decreased by -2.17% |
| Aug 4, 22 | -0.46 Increased by +2.13% | -0.42 Decreased by -9.52% |
| May 5, 22 | -0.41 Increased by +21.15% | -0.48 Increased by +14.58% |
| Mar 10, 22 | -0.51 Increased by +38.55% | -0.46 Decreased by -10.87% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 406 K Decreased by -82.86% | -45.85 M Decreased by -7.21% | Decreased by -11.29 K% Decreased by -525.55% |
| Jun 30, 23 | 0 Decreased by N/A% | -45.55 M Decreased by -8.31% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 1.29 M Increased by +N/A% | -39.81 M Decreased by -7.42% | Decreased by -3.08 K% Decreased by N/A% |
| Dec 31, 22 | 3.83 M Increased by +364.76% | -26.95 M Increased by +35.32% | Decreased by -704.6% Increased by +86.08% |
| Sep 30, 22 | 2.37 M Increased by +N/A% | -42.77 M Decreased by -25.82% | Decreased by -1.81 K% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by -100% | -42.06 M Decreased by -26.79% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by -100% | -37.06 M Decreased by -11.41% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 823 K Increased by +194.27% | -41.67 M Increased by +2.79% | Decreased by -5.06 K% Decreased by -203.12% |
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It also focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.